iFluor® 488 goat anti-rabbit IgG (H+L) Cross Adsorbed

Ordering information

Price
Catalog Number
Unit Size
Quantity

Add to cart

Additional ordering information

Telephone	1-800-990-8053
Fax	1-800-609-2943
Email	sales@aatbio.com
Quotation	Request
International	See distributors
Shipping	Standard overnight for United States, inquire for international

Physical properties

Molecular weight	~150000
Solvent	Water

Spectral properties

Correction Factor (260 nm)	0.21
Correction Factor (280 nm)	0.11
Extinction coefficient (cm ^-1 M ^-1)	75000¹
Excitation (nm)	491
Emission (nm)	516
Quantum yield	0.9¹

Storage, safety and handling

H-phrase	H303, H313, H333
Hazard symbol	XN
Intended use	Research Use Only (RUO)
R-phrase	R20, R21, R22
Storage	Freeze (< -15 °C); Minimize light exposure
UNSPSC	12171501

Alternative formats

iFluor® 488 goat anti-rabbit IgG (H+L)

Overview SDS Protocol

Molecular weight

~150000

Correction Factor (260 nm)

0.21

Correction Factor (280 nm)

0.11

Extinction coefficient (cm ^-1 M ^-1)

75000¹

Excitation (nm)

491

Emission (nm)

516

Quantum yield

0.9¹

AAT Bioquest's iFluor® dyes are optimized for labeling proteins, in particular, antibodies. These dyes are bright, photostable and have minimal quenching on proteins. They can be well excited by the major laser lines of fluorescence instruments (e.g., 350, 405, 488, 555 and 633 nm). iFluor® 488 goat anti-rabbit IgG (H+L) conjugate has fluorescence excitation and emission maxima of ~491 nm and ~514 nm respectively. These spectral characteristics make them an excellent alternative to Alexa Fluor® 488 goat anti-rabbit IgG (H+L) conjugate (Alexa Fluor® is the trademark of Invitrogen).

Spectrum

Open in Advanced Spectrum Viewer

Spectral properties

Correction Factor (260 nm)	0.21
Correction Factor (280 nm)	0.11
Extinction coefficient (cm ^-1 M ^-1)	75000¹
Excitation (nm)	491
Emission (nm)	516
Quantum yield	0.9¹

Product Family

Name	Excitation (nm)	Emission (nm)	Extinction coefficient (cm ^-1 M ^-1)	Quantum yield	Correction Factor (260 nm)	Correction Factor (280 nm)
iFluor® 488 goat anti-mouse IgG (H+L)	491	516	75000¹	0.9¹	0.21	0.11
iFluor® 488 goat anti-mouse IgG (H+L) Cross Adsorbed	491	516	75000¹	0.9¹	0.21	0.11
iFluor® 350 goat anti-rabbit IgG (H+L)	345	450	20000¹	0.95¹	0.83	0.23
iFluor® 405 goat anti-rabbit IgG (H+L)	403	427	37000¹	0.91¹	0.48	0.77
iFluor® 514 goat anti-rabbit IgG (H+L)	511	527	75000¹	0.83¹	0.265	0.116
iFluor® 532 goat anti-rabbit IgG (H+L)	537	560	90000¹	0.68¹	0.26	0.16
iFluor® 555 goat anti-rabbit IgG (H+L)	557	570	100000¹	0.64¹	0.23	0.14
iFluor® 594 goat anti-rabbit IgG (H+L)	588	604	180000¹	0.53¹	0.05	0.04
iFluor® 633 goat anti-rabbit IgG (H+L)	640	654	250000¹	0.29¹	0.062	0.044
iFluor® 647 goat anti-rabbit IgG (H+L)	656	670	250000¹	0.25¹	0.03	0.03
iFluor® 680 goat anti-rabbit IgG (H+L)	684	701	220000¹	0.23¹	0.097	0.094
iFluor® 700 goat anti-rabbit IgG (H+L)	690	713	220000¹	0.23¹	0.09	0.04
iFluor® 750 goat anti-rabbit IgG (H+L)	757	779	275000¹	0.12¹	0.044	0.039
iFluor® 790 goat anti-rabbit IgG (H+L)	787	812	250000¹	0.13¹	0.1	0.09
iFluor® 350 goat anti-rabbit IgG (H+L) Cross Adsorbed	345	450	20000¹	0.95¹	0.83	0.23
iFluor® 405 goat anti-rabbit IgG (H+L) Cross Adsorbed	403	427	37000¹	0.91¹	0.48	0.77
iFluor® 514 goat anti-rabbit IgG (H+L) Cross Adsorbed	511	527	75000¹	0.83¹	0.265	0.116
iFluor® 532 goat anti-rabbit IgG (H+L) Cross Adsorbed	537	560	90000¹	0.68¹	0.26	0.16
iFluor® 555 goat anti-rabbit IgG (H+L) Cross Adsorbed	557	570	100000¹	0.64¹	0.23	0.14
iFluor® 594 goat anti-rabbit IgG (H+L) Cross Adsorbed	588	604	180000¹	0.53¹	0.05	0.04
iFluor® 633 goat anti-rabbit IgG (H+L) Cross Adsorbed	640	654	250000¹	0.29¹	0.062	0.044
iFluor® 647 goat anti-rabbit IgG (H+L) Cross Adsorbed	656	670	250000¹	0.25¹	0.03	0.03
iFluor® 680 goat anti-rabbit IgG (H+L) Cross Adsorbed	684	701	220000¹	0.23¹	0.097	0.094
iFluor® 700 goat anti-rabbit IgG (H+L) Cross Adsorbed	690	713	220000¹	0.23¹	0.09	0.04
iFluor® 750 goat anti-rabbit IgG (H+L) Cross Adsorbed	757	779	275000¹	0.12¹	0.044	0.039
iFluor® 790 goat anti-rabbit IgG (H+L) Cross Adsorbed	787	812	250000¹	0.13¹	0.1	0.09
iFluor® 546 goat anti-rabbit IgG (H+L)	541	557	100000¹	0.67¹	0.25	0.15
iFluor® 546 goat anti-rabbit IgG (H+L) Cross Adsorbed	541	557	100000¹	0.67¹	0.25	0.15
iFluor® 568 goat anti-rabbit IgG (H+L)	568	587	100000¹	0.57¹	0.34	0.15
iFluor® 568 goat anti-rabbit IgG (H+L) Cross Adsorbed	568	587	100000¹	0.57¹	0.34	0.15
iFluor® 800 goat anti-rabbit IgG (H+L)	801	820	250000¹	0.11¹	0.03	0.08
iFluor® 800 goat anti-rabbit IgG (H+L) Cross Adsorbed	801	820	250000¹	0.11¹	0.03	0.08
iFluor® 810 goat anti-rabbit IgG (H+L)	811	822	250000¹	0.05¹	0.09	0.15
iFluor® 810 goat anti-rabbit IgG (H+L) Cross Adsorbed	811	822	250000¹	0.05¹	0.09	0.15
iFluor® 820 goat anti-rabbit IgG (H+L)	822	850	250000¹		0.11	0.16
iFluor® 820 goat anti-rabbit IgG (H+L) Cross Adsorbed	822	850	250000¹		0.11	0.16
iFluor® 840 goat anti-rabbit IgG (H+L)	836	879	200000¹	-	0.2	0.09
iFluor® 840 goat anti-rabbit IgG (H+L) Cross Adsorbed	836	879	200000¹	-	0.2	0.09
iFluor® 860 goat anti-rabbit IgG (H+L)	853	878	250000¹		0.1	0.14
iFluor® 860 goat anti-rabbit IgG (H+L) Cross Adsorbed	853	878	250000¹		0.1	0.14
Show More (31)

Images

Figure 1. HeLa cells were stained with rabbit anti-tubulin followed by iFluor 488 goat anti-rabbit IgG (H+L) *Cross Adsorbed*, and nuclei were stained Nuclear Blue DCS1 (Cat#17548).

Citations

View all 9 citations: Citation Explorer

The inhibitory effects of lobaplatin, or in combination with gemcitabine on triple-negative breast cancer cells in vitro and in vivo
Authors: Jiang, Chengyan and Zhang, Ye and Xu, Xiaoyu and Su, Shanshan and Pan, Huafeng and Jiang, Aiqin
Journal: Oncologie (2023)

Enhancement of pacing function by HCN4 overexpression in human pluripotent stem cell-derived cardiomyocytes
Authors: Saito, Yukihiro and Nakamura, Kazufumi and Yoshida, Masashi and Sugiyama, Hiroki and Akagi, Satoshi and Miyoshi, Toru and Morita, Hiroshi and Ito, Hiroshi
Journal: Stem Cell Research \& Therapy (2022): 1--13

Inducible co-stimulator inhibits lipid phagocytosis of human aortic smooth muscle cells by down-regulating CD36 expression
Authors: Liang, Meng and Guo, Xuemin and Wu, Heming and Zhong, Zhixiong
Journal: Journal of Thoracic Disease (2022): 147

Accelerated onset of cnS prion disease in mice co-infected with a gastrointestinal helminth pathogen during the preclinical phase
Authors: Donaldson, David S and Bradford, Barry M and Else, Kathryn J and Mabbott, Neil A
Journal: Scientific reports (2020): 1--17

Low density culture of mammalian primary neurons in compartmentalized microfluidic devices
Authors: Poddar, Suruchi and Parasa, Mrugesh Krishna and Vajanthri, Kiran Yellappa and Chaudhary, Anjali and Pancholi, Utkarsh Vinodch and ra , undefined and Sarkar, Arnab and Singh, Ashish Kumar and Mahto, Sanjeev Kumar
Journal: Biomedical microdevices (2019): 67

Overexpression of CXCR2 predicts poor prognosis in patients with colorectal cancer.
Authors: Zhao, Jingkun and Ou, Baochi and Feng, Hao and Wang, Puxiongzhi and Yin, Shuai and Zhu, Congcong and Wang, Shenjie and Chen, Chun and Zheng, Minhua and Zong, Yaping and others, undefined
Journal: Oncotarget (2017)

Cadherin-12 enhances proliferation in colorectal cancer cells and increases progression by promoting EMT
Authors: Ma, Junjun and Zhao, Jingkun and Lu, Jun and Wang, Puxiongzhi and Feng, Hao and Zong, Yaping and Ou, Baochi and Zheng, Minhua and Lu, Aiguo
Journal: Tumor Biology (2016): 1--12

Transplantation of RADA16-BDNF peptide scaffold with human umbilical cord mesenchymal stem cells forced with CXCR4 and activated astrocytes for repair of traumatic brain injury
Authors: Shi, W and Huang, CJ and Xu, XD and Jin, GH and Huang, RQ and Huang, JF and Chen, YN and Ju, SQ and Wang, Y and Shi, YW and others, undefined
Journal: Acta Biomaterialia (2016): 247--261

The migration and differentiation of hUC-MSCsCXCR4/GFP encapsulated in BDNF/chitosan scaffolds for brain tissue engineering
Authors: Huang, Chuanjun and Zhao, Longxiang and Gu, Jun and Nie, Dekang and Chen, Yinan and Zuo, Hao and Huan, Wei and Shi, Jinlong and Chen, Jian and Shi, Wei
Journal: Biomedical Materials (2016): 035004

References

View all 191 references: Citation Explorer

Antiprothrombin antibodies in a patient with secondary antiphospholipid syndrome and bleeding
Authors: Gonzalez Leon R, Garcia Hern and ez FJ, Castillo Palma MJ, Sanchez Roman J.
Journal: Med Clin (Barc) (2011): 668

Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers
Authors: Waterhouse BR, Gijsen M, Barber PR, Tullis ID, Vojnovic B, Kong A.
Journal: Oncotarget (2011): 728

Falsely elevated tacrolimus levels caused by immunoassay interference secondary to beta-galactosidase antibodies in an infected liver transplant recipient
Authors: Knorr JP, Grewal KS, Balasubramanian M, Young N, Zaki R, Khanmoradi K, Araya V, Ortiz J.
Journal: Pharmacotherapy (2010): 954

Prevalence of anti-Epstein-Barr virus antibodies in children and adolescents with secondary immunodeficiency
Authors: Buckova A., undefined
Journal: Epidemiol Mikrobiol Imunol (2010): 133

Analysis of the effectiveness of reused primary and secondary antibodies in Western blotting analysis
Authors: Boonrod K, Roth B, Leong Ngar S, Krczal G.
Journal: Anal Biochem (2010): 124

Nanosilver-doped DNA polyion complex membrane for electrochemical immunoassay of carcinoembryonic antigen using nanogold-labeled secondary antibodies
Authors: Wu W, Yi P, He P, Jing T, Liao K, Yang K, Wang H.
Journal: Anal Chim Acta (2010): 126

Three siblings with self-resolving congenital hyperthyrotropinaemia secondary to thyrotropin receptor blocking antibodies
Authors: Azzopardi P, Forrester M, Ehtisham S.
Journal: J Paediatr Child Health (2010): 439

Double-blotting: a solution to the problem of nonspecific binding of secondary antibodies in immunoblotting procedures
Authors: Lasne F., undefined
Journal: Methods Mol Biol (2009): 213

Parkinsonism/dystonia syndrome secondary to multiple sclerosis with anti-basal-ganglia antibodies
Authors: Delgado S, Baez S, Singer C, Sengun C, Sheremata WA, Papapetropoulos S.
Journal: Mov Disord (2009): 309

Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing
Authors: Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K.
Journal: Clin Neuropharmacol (2009): 213